СПИСЪК НА ЦИТИРАНИЯТА

НА ДОЦЕНТ ДИМИТРИНКА ЙОРДАНОВА АТАНАСОВА-ДИМИТРОВА, ДБ

ЗА УЧАСТИЕ В КОНКУРС ЗА ЗАЕМАНЕ НА АКАДЕМИЧНА ДЛЪЖНОСТ „ПРОФЕСОР"

ПО НАУЧНА СПЕЦИАЛНОСТ „МОРФОЛОГИЯ"

В ОБЛАСТ НА ВИСШЕ ОБРАЗОВАНИЕ 4. ПРИРОДНИ НАУКИ, МАТЕМАТИКА И ИНФОРМАТИКА, ПРОФЕСИОНАЛНО НАПРАВЛЕНИЕ 4.3. БИОЛОГИЧЕСКИ НАУКИ

ОБЯВЕН В ДВ БР. 16 (СТРАНИЦА 99) ОТ 23.02.2024 Г.

(номерата на цитираните статии съответстват на тези от общия списък на всички научни трудове)

Група от показатели	***Показател***	***Брой точки***
Д	11. Цитирания в научни издания, монографии, колективни томове и патенти, реферирани и индексирани в световноизвестни бази данни с научна информация (Web of Science и Scopus)	по 2 точки за всяко цитиране
	49. Цитирана статия: Tchekalarova, J., **Atanasova, D.**, Kortenska, L., Atanasova, M., Lazarov, N.E. (2018) Chronic agomelatine treatment prevents comorbid depression in the post-status epilepticus model of acquired epilepsy through suppression of inflammatory signaling. *Neurobiology of Disease* 115, 127-144. SJR (Scopus): 2.665, JCR-IF (Web of Science): 5.16. **Q1**.	
	1. Bayram, F., Reis, R., Tunçer, B., & Sipahi, H. (2018) The importance of the structural similarity of drugs used for depression and inflammation, two comorbid diseases. *Current topics in medicinal chemistry*, *18*(16), 1416-1421.	**2 точки**
	2. Tao, X., Yang, W., Zhu, S., Que, R., Liu, C., Fan, T., Wang, J., Mo, D., Zhang, Z., Tan, J. and Jin, K. (2019) Models of poststroke depression and assessments of core depressive symptoms in rodents: How to choose? *Experimental neurology*, *322*, p.113060.	**2 точки**
	3. Smyk, M. K., van Luijtelaar, G., Huysmans, H., Drinkenburg, W. H. (2019). Spike–wave discharges and sleep–wake states during circadian desynchronization: no effects of agomelatine upon re-entrainment. *Neuroscience*, *408*, 327-338.	**2 точки**
	4. Konstantakopoulos, G., Dimitrakopoulos, S., Michalopoulou, P. G. (2020) The preclinical discovery and development of agomelatine for the treatment of depression. *Expert opinion on drug discovery*, *15*(10), 1121-1132.	**2 точки**

	5. Krishnan, V. (2020) Depression and anxiety in the epilepsies: from bench to bedside. *Current neurology and neuroscience reports*, *20*, 1-12.	**2 точки**
	6. El-Khatib, Y. A., Sayed, R. H., Sallam, N. A., Zaki, H. F., Khattab, M. M. (2020) 17β-Estradiol augments the neuroprotective effect of agomelatine in depressive-and anxiety-like behaviors in ovariectomized rats. *Psychopharmacology*, *237*, 2873-2886.	**2 точки**
	7. van Vuren, E. J., Steyn, S. F., Brink, C. B., Möller, M., Viljoen, F. P., Harvey, B. H. (2021). The neuropsychiatric manifestations of COVID-19: Interactions with psychiatric illness and pharmacological treatment. *Biomedicine & Pharmacotherapy*, *135*, 111200.	**2 точки**
	8. Peng, W., Shen, Y., Wang, Q., Ding, J., & Wang, X. (2021). TPPU Pre-treatment rescues dendritic spine loss and alleviates depressive behaviours during the latent period in the lithium chloride-pilocarpine-induced status epilepticus rat model. *Brain Sciences*, *11*(11), 1465.	**2 точки**
	9. Mazza, M. G., Palladini, M., Poletti, S., & Benedetti, F. (2022) Post-COVID-19 depressive symptoms: epidemiology, pathophysiology, and pharmacological treatment. *CNS drugs*, *36*(7), 681-702.	**2 точки**
	10. Kholghi, G., Eskandari, M., Saadlou, M. S. S. Q., Zarrindast, M. R., & Vaseghi, S. (2022) Night shift hormone: How does melatonin affect depression?. *Physiology & Behavior*, *252*, 113835.	**2 точки**
	11. Ryan-Coats, S.K., Hughes, S.D., Holz, F.M., Kreger, R.B., Koulibali, C.I., Khan, H.A., Harris, K.C., Kelly, A.E. and Epps, S.A. (2022) Something new and something blue: Responses to novelty in a rodent model of depression and epilepsy comorbidity. *Physiology & Behavior*, *249*, p.113778.	**2 точки**
	12. Bialek, K., Czarny, P., Wigner, P., Synowiec, E., Kolodziej, L., Bijak, M., Szemraj, J., Papp, M. and Sliwinski, T. (2022) Agomelatine Changed the Expression and Methylation Status of Inflammatory Genes in Blood and Brain Structures of Male Wistar Rats after Chronic Mild Stress Procedure. *International Journal of Molecular Sciences*, *23*(16), p.8983.	**2 точки**
	13. Fang, M., Liu, W., Tuo, J., Liu, M., Li, F., Zhang, L., Yu, C. and Xu, Z. (2023) Advances in understanding the pathogenesis of post-traumatic epilepsy: A literature review. *Frontiers in Neurology*, *14*, p.1141434.	**2 точки**

	14. Ding, R., Han, Z., Gui, J., Xie, L., Yang, J., Yang, X., Huang, D., Luo, H., Han, W. and Jiang, L. (2023) Inflammatory properties of diet mediate the effect of epilepsy on moderate to severe depression: Results from NHANES 2013–2018. *Journal of Affective Disorders*, *331*, pp.175-183. 15. De, A., Grasing, K. W. (2023) The antidepressant agomelatine attenuates morphine-induced reinstatement but not self-administration or precipitated withdrawal. *Pharmacology Biochemistry and Behavior*, *223*, 173525.	**2 точки** **2 точки**
	61. Цитирана статия: Ilieva, K., Tchekalarova, J., **Atanasova, D.**, Kortenska, L., Atanasova, M. (2019) Antidepressant agomelatine attenuates behavioral deficits and concomitant pathology observed in streptozotocin-induced model of Alzheimer's disease in male rats. Hormones and Behavior 107, 11-19. SJR (Scopus): 1.632, JCR-IF 2018 (Web of Science): 3.949. **Q1.**	
	16. Konstantakopoulos, G., Dimitrakopoulos, S., & Michalopoulou, P. G. (2020). The preclinical discovery and development of agomelatine for the treatment of depression. *Expert opinion on drug discovery*, *15*(10), 1121-1132. 17. Yu, Z., Wang, J., Wang, H., Wang, J., Cui, J., & Junzhang, P. (2020). Effects of sevoflurane exposure during late pregnancy on brain development and beneficial effects of enriched environment on offspring cognition. *Cellular and molecular neurobiology*, *40*, 1339-1352. 18. Gáspár, A., Hutka, B., Ernyey, A. J., Tajti, B. T., Varga, B. T., Zádori, Z. S., & Gyertyán, I. (2021). Intracerebroventricularly injected streptozotocin exerts subtle effects on the cognitive performance of long-evans rats. *Frontiers in Pharmacology*, *12*, 662173. 19. Flores-Cuadra, J. A., Madrid, A., Fernandez, P. L., Perez-Lao, A. R., Oviedo, D. C., Britton, G. B., & Carreira, M. B. (2021). Critical Review of the Alzheimer's Disease Non-Transgenic Models: Can They Contribute to Disease Treatment?. *Journal of Alzheimer's Disease*, *82*(s1), S227-S250. 20. Peng, X., Fan, R., Xie, L., Shi, X., Dong, K., Zhang, S., Tao, J., Xu, W., Ma, D., Chen, J. and Yang, Y., 2022. A growing link between circadian rhythms, type 2 diabetes mellitus and Alzheimer's disease. *International journal of molecular sciences*, *23*(1), p.504.	**2 точки** **2 точки** **2 точки** **2 точки** **2 точки**

	21. Roy, J., Wong, K.Y., Aquili, L., Uddin, M.S., Heng, B.C., Tipoe, G.L., Wong, K.H., Fung, M.L. and Lim, L.W. (2022) Role of melatonin in Alzheimer's disease: from preclinical studies to novel melatonin-based therapies. *Frontiers in neuroendocrinology*, *65*, p.100986.	**2 точки**
	22. Gáspár, A., Hutka, B., Ernyey, A.J., Tajti, B.T., Varga, B.T., Zádori, Z.S. and Gyertyán, I. (2022) Performance of the intracerebroventricularly injected streptozotocin Alzheimer's disease model in a translationally relevant, aged and experienced rat population. *Scientific Reports*, *12*(1), p.20247.	**2 точки**
	23. Li, T., Su, Q., Zhang, Z., Zhang, Y., Yang, M., Wang, Z., Guo, J., Wang, Z., Wu, M., Cai, H. and Qi, J., 2022. Ube2c-inhibition alleviated amyloid pathology and memory deficits in APP/PS1 mice model of AD. *Progress in neurobiology*, *215*, p.102298.	**2 точки**
	24. Liu, H., Zhong, L., Dai, Q., Yang, J., Zhang, Y., Zhang, B. and Jiang, Y., 2022. Zuoguiwan ameliorates cognitive deficits and neuro-inflammation in streptozotocin-induced Alzheimer's disease rats. *Neuroimmunomodulation*, *29*(1), pp.63-69.	**2 точки**
	25. Yang, X.B., Zu, H.B., Zhao, Y.F. and Yao, K., 2022. Agomelatine prevents amyloid plaque deposition, tau phosphorylation, and neuroinflammation in APP/PS1 mice. *Frontiers in aging neuroscience*, *13*, p.766410.	**2 точки**
	26. Su, Q., Li, T., Liu, G.W., Zhang, Y.L., Guo, J.H., Wang, Z.J., Wu, M.N. and Qi, J.S., 2023. Agomelatine: a potential novel approach for the treatment of memory disorder in neurodegenerative disease. *Neural Regeneration Research*, *18*(4), pp.727-733.	**2 точки**
	27. Piao, J., Wang, Y., Zhang, T., Zhao, J., Lv, Q., Ruan, M., Yu, Q. and Li, B., 2023. Antidepressant-like Effects of Representative Types of Food and Their Possible Mechanisms. *Molecules*, *28*(19), p.6992.	**2 точки**
	28. Farhangian, M., Azarafrouz, F., Chavoshinezhad, S. and Dargahi, L., 2023. Intranasal interferon-beta alleviates anxiety and depressive-like behaviors by modulating microglia polarization in an Alzheimer's disease model. *Neuroscience letters*, *792*, p.136968.	**2 точки**
	29. Nesterowicz, M., Lauko, K.K., Żendzian-Piotrowska, M., Ładny, J.R., Zalewska, A. and Maciejczyk, M., 2023.	**2 точки**

	Agomelatine's antiglycoxidative action—In vitro and in silico research and systematic literature review. *Frontiers in Psychiatry*, *14*, p.1164459. 30. King, H., Reiber, M., Philippi, V., Stirling, H., Aulehner, K., Bankstahl, M., Bleich, A., Buchecker, V., Glasenapp, A., Jirkof, P. and Miljanovic, N., 2023. Anesthesia and analgesia for experimental craniotomy in mice and rats: a systematic scoping review comparing the years 2009 and 2019. *Frontiers in Neuroscience*, *17*, p.1143109.	**2 точки**
	69. Цитирана статия: Tchekalarova, J., Stoyanova, Tz., Nenchovska, Zl., Ivanova, N., Atanasova, D., Atanasova, M., Georgieva, K. (2020): Effect of endurance training on diurnal rhythms of superoxide dismutase activity, glutathione and lipid peroxidation in plasma of pinealectomized rats. Neuroscience Letters, 716, 134637. ISSN:0304-3940, DOI:10.1016/j.neulet.2019.134637, 1-6, SJR 2020 (Scopus):0.944, JCR-IF 2020 (Web of Science): 2.78. **Q2**.	
	31. Kennaway, D.J. (2020) Measuring melatonin by immunoassay. *Journal of Pineal Research*, *69*(1), p.e12657. 32. Sadanandan, N., Cozene, B., Cho, J., Park, Y.J., Saft, M., Gonzales-Portillo, B. and Borlongan, C.V. (2020) Melatonin—A potent therapeutic for stroke and stroke-related dementia. *Antioxidants*, *9*(8), p.672. 33. Kennaway, D.J. (2021) Can we believe results obtained from plasma melatonin ELISA kits?. *Chronobiology International*, *38*(4), pp.616-619. 34. Maia Ladeira, L.C., Santos, C.F.F., de Deus, F.A., Gomes, A.R., Bastos, D.S.S., Souza, A.C.F. and dos Santos, E.C., (2021) Chronic caffeine use does not influence behavior and brain oxidative status in mice. *Revista da Associação Brasileira de Nutrição*, *12*(2). 35. Genovese, T., Impellizzeri, D., D'Amico, R., Cordaro, M., Peritore, A.F., Crupi, R., Gugliandolo, E., Cuzzocrea, S., Fusco, R., Siracusa, R. and Di Paola, R. (2022) Resveratrol inhibition of the WNT/β-catenin pathway following discogenic low back pain. *International Journal of Molecular Sciences*, *23*(8), p.4092. 36. Yui, K., Imataka, G., Hayashi, T., Koshiba, M., Shiko, Y., Kawasaki, Y. and Sasai, H. (2022) Contribution of lipid Peroxidation to Social Behaviors in individuals with autism spectrum disorders.	**2 точки** **2 точки** **2 точки** **2 точки** **2 точки** **2 точки**

	37. Kennaway, D.J., 2023. The mammalian gastro-intestinal tract is a NOT a major extra-pineal source of melatonin. *Journal of Pineal Research*, *75*(4), p.e12906. 38. Cervino, C.O., Pagella, J.C. and Hernando, M., 2023. Effects of long-term exposure to light or darkness and return to normal light-dark cycle on serum melatonin levels in rats. *Melatonin Research*, *6*(2), pp.215-223.	**2 точки** **2 точки**
	78. Цитирана работа: Shishmanova-Doseva, M., **Atanasova, D.**, Uzunova, Y., Yoanidu, L., Peychev, L., Marinov, P., Tchekalarova, J. (2021) Effects of Lacosamide Treatment on Epileptogenesis, Neuronal Damage and Behavioral Comorbidities in a Rat Model of Temporal Lobe Epilepsy. International Journal of Molecular Sciences, 22(9), 4667. MDPI, ISSN:1422-0067, DOI: 10.3390/ijms22094667. SJR (Scopus): 0.923, JCR-IF (Web of Science): 6.208 **Q1**.	
	39. Yang, J., Jia, Z., Xiao, Z., Zhao, J., Lu, Y., Chu, L., Shao, H., Pei, L., Zhang, S. and Chen, Y., 2021. Baicalin rescues cognitive dysfunction, mitigates neurodegeneration, and exerts anti-epileptic effects through activating TLR4/MYD88/caspase-3 pathway in rats. *Drug Design, Development and Therapy*, pp.3163-3180. 40. Kandeda, A.K., Menvouta, S., Mabou, S.T., Kouamouo, J. and Dimo, T., 2022. Aqueous extract of Parkia biglobosa (Jacq.) R. Br.(Fabaceae) exerts antiepileptogenic, anti-amnesic, and anxiolytic-like effects in mice via mechanisms involving antioxidant and anti-inflammatory pathways. *Frontiers in Pharmacology*, *13*, p.995881. 41. Corvace, F., Faustmann, T.J., Faustmann, P.M. and Ismail, F.S., 2022. Anti-inflammatory properties of lacosamide in an astrocyte-microglia co-culture model of inflammation. *European Journal of Pharmacology*, *915*, p.174696. 42. Wu, Q., Wang, H., Liu, X., Zhao, Y. and Zhang, J., 2022. The role of the negative regulation of microglia-mediated neuroinflammation in improving emotional behavior after epileptic seizures. *Frontiers in Neurology*, *13*, p.823908. 43. Sumbul, O. and Aygun, H., 2022. Electrocorticographic and electrocardiographic evaluation of lacosamide in a penicillin-induced status epilepticus model. *Epilepsy Research*, *180*, p.106866. 44. Carcak, N., Karanfil, C., Akat, Ş., Akman, Ö. and Onat, F., 2022. The effect of chronic treatment with sodium channel blocker lacosamide on early development of absence	**2 точки** **2 точки** **2 точки** **2 точки** **2 точки** **2 точки**

	seizures in genetic absence epilepsy rats. *Epilepsy Research*, *182*, p.106896. 45. He, Z. and Li, J., 2023. The therapeutic effects of lacosamide on epilepsy-associated comorbidities. *Frontiers in Neurology*, *14*, p.1063703.	**2 точки**
	73. Цитирана статия: **Atanasova, D.**, Lazarov, N., Stoyanov, D., Spassov, R., Tonchev, A., Tchekalarova, J. (2021) Reduced neuroinflammation and enhanced neurogenesis following chronic agomelatine treatment in rats undergoing chronic constant light. Neuropharmacology, 127, 108706. Elsevier, ISSN:0028-3908, DOI: 10.1016/j.neuropharm.2021.108706, SJR (Scopus):1.323, JCR-IF (Web of Science):5.273 **Q1**.	
	46. Wang, Y.Q., Jiang, Y.J., Zou, M.S., Liu, J., Zhao, H.Q. and Wang, Y.H., 2022. Antidepressant actions of melatonin and melatonin receptor agonist: Focus on pathophysiology and treatment. Behavioural brain research, 420, p.113724. 47. Zhang, Q., Jin, K., Chen, B., Liu, R., Cheng, S., Zhang, Y. and Lu, J., 2022. Overnutrition induced cognitive impairment: insulin resistance, gut-brain axis, and neuroinflammation. *Frontiers in Neuroscience*, *16*, p.884579. 48. Liu, Q., Wang, Z., Cao, J., Dong, Y. and Chen, Y., 2022. Dim blue light at night induces spatial memory impairment in mice by hippocampal neuroinflammation and oxidative stress. *Antioxidants*, *11*(7), p.1218. 49. Kholghi, G., Eskandari, M., Saadlou, M.S.S.Q., Zarrindast, M.R. and Vaseghi, S., 2022. Night shift hormone: How does melatonin affect depression?. *Physiology & Behavior*, *252*, p.113835. 50. Navarro-Gil, F.J., Huete-Toral, F., Domínguez-Godínez, C.O., Carracedo, G. and Crooke, A., 2022. Contact lenses loaded with melatonin analogs: a promising therapeutic tool against dry eye disease. *Journal of Clinical Medicine*, *11*(12), p.3483. 51. Potes, Y., Cachán-Vega, C., Antuña, E., García-González, C., Menéndez-Coto, N., Boga, J.A., Gutiérrez-Rodríguez, J., Bermúdez, M., Sierra, V., Vega-Naredo, I. and Coto-Montes, A., 2023. Benefits of the Neurogenic Potential of Melatonin for Treating Neurological and Neuropsychiatric Disorders. *International Journal of Molecular Sciences*, *24*(5), p.4803. 52. Wang, Y.B., Song, N.N., Ding, Y.Q. and Zhang, L., 2023. Neural plasticity and depression treatment. *IBRO*	**2 точки** **2 точки** **2 точки** **2 точки** **2 точки** **2 точки**

	Neuroscience Reports, *14*, pp.160-184. 53. Meng, D., Yang, M., Zhang, H., Zhang, L., Song, H., Liu, Y., Zeng, Y., Yang, B., Wang, X., Chen, Y. and Liu, R., 2023. Microglia activation mediates circadian rhythm disruption-induced cognitive impairment in mice. *Journal of neuroimmunology*, *379*, p.578102. 54. Nagata, W., Koizumi, A., Nakagawa, K., Takahashi, S., Gotoh, M., Satoh, Y. and Ishizuka, T., 2023. Treatment with lysophosphatidic acid prevents microglial activation and depression-like behaviours in a murine model of neuropsychiatric systemic lupus erythematosus. *Clinical and Experimental Immunology*, *212*(2), pp.81-92.	**2 точки** **2 точки**
	60. Цитирана статия:Tchekalarova, J., **Atanasova, D.**, Kortenska, L., Lazarov, N., Shismanova-Doseva, M., Galchev, Tz., Marinov, P. (2019) Agomelatine alleviates neuronal loss through BDNF signaling in the post-status epilepticus model induced by kainic acid in rat. *Brain Research Bulletin* 147, 22-35. SJR (Scopus): 1.079, JCR-IF (Web of Science): 3.103. **Q2**.	
	55. Sumbul, O. and Aygun, H., 2022. Electrocorticographic and electrocardiographic evaluation of lacosamide in a penicillin-induced status epilepticus model. *Epilepsy Research*, *180*, p.106866	**2 точки**
	Общо от цитирания:	**110 точки**